Name: Anti-Human CD3 Monoclonal Antibodies
Brand: Syd Labs
SKU: PA007197
Price: 150.00 USD
Availability: InStock
Rating: 5 (10 reviews)

Catalog No.

Product Name

Size

List Price (US$)

Quantity

PA007197

In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody, Mouse IgG1 Kappa (Clone: UCHT1)

1 mg

150.00

PA007197

In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody, Mouse IgG1 Kappa (Clone: UCHT1)

5 mg

350.00

PA007197

In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody, Mouse IgG1 Kappa (Clone: UCHT1)

25 mg

900.00

PA007197.h1

In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody, Human IgG1 Kappa (Clone: UCHT1)

1 mg

150.00

PA007197.h1

In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody, Human IgG1 Kappa (Clone: UCHT1)

5 mg

350.00

PA007197.h1

In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody, Human IgG1 Kappa (Clone: UCHT1)

25 mg

900.00

Description

PA007197: In vivo Grade Recombinant Anti-human CD3 Mouse IgG1 Kappa Monoclonal Antibody (Clone: UCHT1)

Recombinant mouse IgG1 Monoclonal Antibody.
Clone: UCHT1.
Isotype: Mouse IgG1 kappa.
Source: The anti-human CD3 monoclonal antibody (clone: UCHT1) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: UCHT1) specifically binds to the human T cell receptor CD3.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD3 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

References of anti-human CD3e antibody (UCHT1):

In vivo DNA-launched bispecific T cell engager targeting IL-13R?2 limits tumor growth in a humanized mouse model
Wei J, et al. Mol Ther Oncolytics. 2022 Sep 16;27:106-116. doi: 10.1016/j.omto.2022.09.006. PMID: 36198095
This study evaluates a DNA-launched bispecific T cell engager (BiTE) targeting IL-13R?2 in a humanized NSG mouse model engrafted with human PBMCs. Flow cytometry analysis utilized anti-human CD45 (HI30), anti-human CD3 (UCHT1), anti-human CD4 (OKT4), anti-human CD8 (SK1), and anti-human PD-1 (EH12.2H7) antibodies. Tumor volumes were measured twice weekly using calipers, calculated as (length × width?)/2. The IL-13R?2 BiTE, delivered via hydrodynamic injection of plasmid DNA, significantly reduced tumor growth compared to controls.
Tags: anti-human CD3e UCHT1; anti-human CD3e UCHT1 in vivo

SCENITH: A Flow Cytometry-Based Method to Functionally Profile Energy Metabolism with Single-Cell Resolution
Argüello RJ, et al. Cell Metab. 2020 Dec 1;32(6):1063-1075.e7. doi: 10.1016/j.cmet.2020.11.007. PMID: 32916098
This study introduces SCENITH, a flow cytometry-based method to profile energy metabolism at single-cell resolution. Immune cell phenotyping was performed using antibodies including anti-CD45 (HI30), anti-CD3 (UCHT1), anti-CD4 (RPA-T4), anti-CD8 (SK1), anti-CD11b (ICRF44), and anti-CD19 (HIB19). Mice were injected with 2-deoxyglucose to inhibit glycolysis, and spleens were processed into single-cell suspensions for analysis. SCENITH measures protein synthesis rates as a proxy for cellular energy metabolism, validated in both mouse and human immune cells.
Tags: anti-human CD3e UCHT1 antibody; bioactivity of anti-human CD3e UCHT1

An IgG-based bispecific antibody for improved dual targeting in vivo
Kellner S, et al. EMBO Mol Med. 2020 May 8;12(5):e11902. doi: 10.15252/emmm.201911902. PMID: 32187521
This study investigates an IgG-based bispecific antibody in NSG mice engrafted with human PBMCs and tumor cells. T cells were stained with anti-CD3 (UCHT1) and anti-CD8 (SK1) antibodies for flow cytometry analysis. Tumor growth was monitored via bioluminescence imaging using an IVIS Spectrum system. The bispecific antibody was administered intravenously at 0.5 mg/kg weekly, with peripheral blood analyzed for T cell activation and cytokine release post-treatment.
Tags: anti-human CD3e UCHT1 of low endotoxin; anti-human CD3e UCHT1 antibody of low endotoxin

In vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and in vivo Toxicology in Non-Human Primates
Wang C, et al. Cancer Immunol Res. 2014 Sep;2(9):846-56. doi: 10.1158/2326-6066.CIR-14-0040. PMID: 24872062
This study characterizes the anti-PD-1 antibody nivolumab in vitro and evaluates its toxicology in cynomolgus monkeys. Flow cytometry was performed using anti-CD3 (UCHT1), anti-CD4 (L200), and anti-CD8 (RPA-T8) antibodies. Monkeys were dosed with nivolumab at 10, 50, or 100 mg/kg weekly for 4 weeks, with peripheral blood samples collected at multiple time points. Nivolumab binding to PD-1 was confirmed on activated T cells, and no significant toxicity was observed at any dose level.
Tags: anti-human CD3e antibody (UCHT1); anti-human CD3e UCHT1

Preclinical evaluation of light-activatable, bispecific anti-human CD3 antibody conjugates as anti-ovarian cancer therapeutics
Staroverov RMT, et al. Mol Cancer Ther. 2009 Jun;8(6):1665-74. doi: 10.1158/1535-7163.MCT-08-1160. PMID: 19509135
This study evaluates light-activatable UCHT1-folate conjugates in nude mice bearing ovarian cancer xenografts. Flow cytometry confirmed T cell binding using anti-CD3 (UCHT1) antibody. Tumors were irradiated with 690 nm light to activate the conjugate, and tumor volumes were measured every 3 days using calipers. The conjugate significantly reduced tumor growth compared to non-irradiated controls.
Tags: clone UCHT1 of anti-human CD3e mAb; UCHT1 anti-human CD3e antibody